Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulipristal versus standard surgical treatment in symptomatic uterine fibroids
2024-512602-26-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ulipristal in Fibromyoma (LM) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Uterine fibroid symptom severity score at 24 months and Costs (direct healthcare, productivity loss, patient costs). Planned start Dec 2024; status: authorised.
02
Drugs
ulipristal
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on 2024-512602-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512602-26-00.